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Abstract: Leiomyosarcoma is a heterogeneous tumor group, representing  1% of all new cancers diagnosed in United States.   
Treatment choice is based upon site, grade, and extent of disease. However, prognosis for metastatic or unresectable sarcoma is very 
poor with reported median survival of 12 months.  Response to chemotherapy has been approximately 8% to 39% based upon the 
chemotherapeutic agent and whether used alone or in combination.  Vorinostat is an orally active, potent, and competitive inhibitor 
of histone deacetylases approved for cutaneous T-cell lymphoma. There are limited preclinical data illustrating the activity of histone 
deacetylase inhibitors in sarcoma.  Here is a case of a lady with leiomyosarcoma who has progressed through multiple chemotherapeutic 
agent who has achieved a partial response to vorinostat treatment.
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Introduction
Soft tissue sarcomas are a rare heterogeneous tumor 
group,  representing  1%  (approximately  10,000 
cases)  of  all  new  cancers  diagnosed  yearly  in  the 
United States.1 Over 50 subtypes of malignant soft 
tissue  sarcomas  have  been  described  in  adults,2 
leiomyosarcomas  are  one  of  the  most  common.2 
Leiomyosarcomas  are  tumors  of  distinct  smooth 
muscle  type  cells  and  occur  intramuscularly  and 
subcutaneously.2
Treatment choices for leiomyosarcomas are influ-
enced by the site, grade, and extent of disease, and 
may include surgery, chemotherapy, and radiotherapy. 
Surgical resection offers the best chance of cure and 
is sometimes coupled with radiotherapy.3 However, 
metastatic or unresectable sarcoma is rarely curable 
with reported median survival time of approximately 
12 months and 5-year survival rates of 10%–15%.4 
Chemotherapy  may  have  substantial  benefits  for 
patients  with  metastatic  or  unresectable  sarcoma 
and of the agents that have been utilized to treat soft 
  tissue sarcomas, the most common are doxorubicin, 
ifosfamide,  and,  more  recently,  gemcitabine,  both 
alone and in combination with taxanes.5 However, 
repeated and/or prolonged use of these agents is pro-
hibited  by  their  limited  efficacy  and/or  associated 
  toxicity. Response rates of approximately 20%, 39%, 
8%, and 16% have been reported for doxorubicin, ifos-
famide, gemcitabine alone, and in combination with 
docetaxel,  respectively.5–7  In  addition,  radiotherapy 
has  been  combined  with  chemotherapy  as  well  as 
being used alone to treat unresectable sarcoma.3
Vorinostat (Zolinza®, Merck Sharp & Dohme, a 
subsidiary of Merck & Co., Inc.), an orally active, 
potent, and competitive inhibitor of histone deacety-
lases (HDAC),8 was approved by the US Food and 
Drug Administration (FDA) in October 2006 for the 
treatment  of  cutaneous  manifestations  in  patients 
with cutaneous T-cell lymphoma (CTCL) who have 
progressive,  persistent,  or  recurrent  disease  on  or 
  following  two  systemic  therapies.9  In  addition  to 
efficacy in hematologic malignances, vorinostat has 
demonstrated  promising  efficacy  in  Phase  I    trials 
in  a  wide  range  of  solid  malignancies.10  Here  we 
report on a female patient with leiomyosarcoma with 
an  apparent  response  to  vorinostat  treatment  after 
  multiple previous chemotherapy treatments.
Case Report
In  September  2005,  a  43-year-old,  asymptomatic 
female presented with an increasing mass (4 × 3 cm) 
in  her  left  thigh  which  involved  the  subcutaneous 
tissue  down  to  the  muscular  fascia  and  adductor 
canal. An immunohistochemical examination on the 
excised tumor confirmed it was positive for smooth 
muscle  actin,  heavy  chain  myosin,  vimentin,  and 
S100 protein. Hence, the tumor was identified as a 
sarcoma consistent with leiomyosarcoma. Additional 
biopsies  performed  during  the  patient’s  therapy 
confirmed this initial diagnosis. Once leiomyosarcoma 
was  diagnosed  the  patient  underwent  computed 
tomography (CT) of the chest, abdomen, and pelvis 
which revealed multiple lung nodules and a tumor 
(2.2  cm  rounded  structure)  in  the  myometrium  of 
the left side of the uterine wall, which effaced the 
uterine cavity. The uterine tumor was c-kit estrogen/
progesterone receptor negative; however, its origin 
was inconclusive. The patient initially (October 2005) 
received combination chemotherapy of doxorubicin 
(50  mg/m2),  ifosfamide  (2000  mg/m2),  and  mesna 
(2000 mg/m2) every 21 days for a total of 6 cycles 
(finishing  January  2006). A  partial  response  based 
upon the CT findings was achieved.
Regretfully, disease recurred 6 months later and 
the above treatment regimen was resumed for 4 cycles 
(finishing  October  2006).  Once  more,  the  patient 
responded well until disease recurred again approxi-
mately  4  months  later;  when  combination  chemo-
therapy with gemcitabine (800 mg/m2) and docetaxel 
(75  mg/m2) was commenced. However, the patient 
developed Grade 4 mucositis and pancytopenia during 
the  first  cycle  necessitating  hospital  admission  and 
treatment was subsequently reduced to single-agent 
gemcitabine (1000 mg/m2, once weekly for 2 weeks 
followed by 1 week rest). The patient responded well 
and received 5 single-agent gemcitabine cycles in total 
(finishing April 2007).
Disease again recurred approximately 4 months 
later  and  treatment  with  single-agent  gemcitabine 
was resumed; however, CT showed disease progres-
sion after 2 cycles and combination chemotherapy 
of doxorubicin, ifosfamide, and mesna was recom-
menced once more. However, after 2 cycles of this 
combination, no response was observed. Confronted 
with  a  lack  of  established  therapy  options  in  this 
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setting,  the  patient  was  offered  the  opportunity  to 
either  enter  a  clinical  trial  or  receive  vorinostat. 
  Vorinostat was   recommended based on Phase I results 
in patients with refractory solid tumors.10 Vorinostat 
(400 mg/day) was started approximately 2 years after 
diagnosis (November 2007), stable disease (SD) was 
observed after 6 weeks and maintained. Furthermore, 
some shrinkage was observed at 3 months in both her 
liver and lung metastases. The patient experienced 
mild nausea initially which subsided after a couple 
of months. Her complete blood count and metabolic 
  values remained within normal limits whilst receiving 
vorinostat.
The patient remained on vorinostat for 18 months 
(finishing April 2009) when she developed progressive 
disease  and  subsequently  received  single-agent 
ifosfamide,  and  mesna  which  failed  to  produce  a 
response.  The  patient  then  received  single-agent 
dacarbazine  followed  by  single-agent  paclitaxel, 
both  of  which  failed  to  produce  a  response. After 
evaluating all of her treatment options, the patient 
selected doxorubicin therapy despite the cardiac risk; 
however, after two cycles of weekly chemotherapy, 
with no response, treatment was stopped. The patient 
then chose to enter a hospice and died approximately 
3.5 years after diagnosis (July 2009).
Discussion
In  common  with  many  patients  with  recurrent 
relapsing leiomyosarcoma, our patient had exhausted 
all    treatment  options  for  effective  chemotherapy; 
including  first-  and  second-line  combination 
  chemotherapy of doxorubicin, ifosfamide, and mesna 
  followed by combination gemcitabine and docetaxel 
which was stopped due to Grade 4 adverse events 
(AEs) and replaced with single-agent gemcitabine, 
followed by doxorubicin, ifosfamide, and mesna upon 
relapse. The best and longest duration of response, 
overall  SD  for  over  1.5  years,  was  achieved  with 
vorinostat  (400  mg/day),  with  initial  mild  nausea 
which resolved, and with some metastases shrinkage. 
Our case is the first to report an apparent effect of 
vorinostat  in  the  treatment  of  leiomyosarcoma. 
Vorinostat  has  been  approved  for  the  treatment  of 
CTCL and has shown efficacy in a number of additional 
hematologic malignancies.11–17 and promising efficacy 
in other solid tumor types such as breast cancer, lung 
cancer, and mesothelioma.10,18–23 In a Phase IIb study 
in patients with persistent, progressive, or recurrent 
CTCL  the  objective  response  rate  with  vorinostat 
monotherapy was 29.7%, and 32.3% of patients (with 
baseline  pruritus  scores  $3)  had  pruritus  relief.11 
The most common drug-related AEs were diarrhea, 
fatigue,  nausea,  and  anorexia,  most  of  which 
were #grade 2; AEs of Grade 3 and above included 
fatigue,  pulmonary  embolism,  thrombocytopenia, 
and nausea.11 In an extension study, patients who had 
completed $6 months of treatment in the Phase IIb 
study were eligible to continue vorinostat treatment, 
until disease progression or unacceptable toxicity.24 
Fifteen of the initial 74 patients entered the extension 
study and six of these patients continued on vorinostat 
therapy for more than 2 years. The most common drug-
related AEs in the continuation study were diarrhea, 
nausea, fatigue, and alopecia and the incidence of 
Grade 3–4 AEs was low. To date, five patients have 
discontinued vorinostat and one patient continues to 
respond after 1445 days (4.0 years). Both the clinical 
trials and post-trial clinical experience have confirmed 
the efficacy and tolerability of vorinostat. Compared 
with conventional cytotoxic agents,5 vorinostat has a 
favorable tolerability profile with both short- and long-
term use.11,24 Thus unlike the cytotoxics, vorinostat 
has the potential for extended use.
A variety of genetic changes have been observed 
in leiomyosarcoma, often including changes in TP53 
and  MDM2  expression,  overexpression  of  cyclin-
dependent kinase inhibitor 2A (CDKN2A; p16), and a 
loss of gamma-smooth muscle isoactin expression.25–27 
These  findings  support  a  preclinical  rationale  for 
the  potential  clinical  utility  of  targeted  agents  in 
the  management  of  leiomyosarcoma.  Vorinostat  is 
a small molecule inhibitor of Class I and II HDAC 
enzymes, which catalyze the removal of acetyl groups 
from histone proteins on nucleosomes, with histone 
acetyltransferases (HATs) facilitating the acetylation 
of these proteins.28 Histone hypoacetylation results 
in  closed  chromatin  structures  and  repression  of 
important  tumor  suppressor  genes.29  Consequently, 
HAT  inactivation  has  been  associated  with 
tumorigenesis and aberrant HDAC activity has been 
related to the development and maintenance of human 
tumors, including CTCL.30 In addition, HDACs have 
many other non-histone proteins as substrates, such 
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as transcription factors (p53), α-tubulin, heat shock 
protein 90 (Hsp90) and various signaling proteins.28
There  are  limited  preclinical  data  reporting  the 
activity  of  HDAC  inhibitors  in  sarcoma.31–39  Ecke 
and  co-workers  observed  that  combined  5-aza-
2′deoxycytidine  (a  DNA  methylation  inhibitor) 
and  valproic  acid  (a  HDAC  inhibitor)  efficiently 
prevented medulloblastoma and rhabdomyosarcoma 
formation  in  patched  mutant  mice.32  Nguyen  and 
co-workers observed that the Hsp90 inhibitor 17-AAG 
and  the  HDAC  inhibitor  MS-275  had  synergistic, 
antiproliferative, and proapoptotic effects on synovial 
sarcoma in vitro.31 Additionally, the HDAC inhibitors 
MS-275,  trichostatin-A,  phenylbutyrate,  LAQ824, 
and  depsipeptide,  enhanced  the  antineoplastic 
action of 5-aza-2′deoxycytidine on Ewings sarcoma 
cells.33  While  Sakimura  and  colleagues  noted  that 
depsipeptide inhibited chondrosarcoma cell growth, 
up-regulated the expression of aggrecan and alpha2 
chain  of  type  XI  collagen  (COL11A2)  mRNA, 
and  induced  differentiation  to  a  hypertrophic  cell 
phenotype.37  Two  studies  with  vorinostat  have 
reported growth inhibition of chondrosarcoma cells, 
significant inhibition of tumor growth in a xenograft 
model,  and  death  of  endometrial  stromal  sarcoma 
cells.34,36 This  case,  which  demonstrates  promising 
activity for vorinostat in leiomyosarcoma, represents 
one  of  the  first  clinical  applications  of  an  HDAC 
inhibitor  in  soft  tissue  sarcoma.  However,  this  is 
only one case report and more studies are needed 
to confirm the activity and efficacy of vorinostat in 
leiomyosarcoma.
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